Muscular Dystrophy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Muscular Dystrophy stocks.

Muscular Dystrophy Stocks Recent News

Date Stock Title
May 16 FULC Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
May 15 FULC Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
May 15 SLDB Solid Biosciences reports Q1 results
May 15 SLDB Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
May 15 LIFE aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
May 14 LIFE aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
May 14 FULC Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
May 14 FULC Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 13 FULC Fulcrum upgraded by Goldman Sachs ahead of Phase 3 data
May 13 FULC Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
May 13 FULC Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
May 13 FULC Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript
May 13 FULC Sanofi gains license for ex-U.S. rights to Fulcrum muscular dystrophy candidate
May 13 FULC Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
May 13 FULC Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
May 13 FULC Fulcrum Therapeutics GAAP EPS of -$0.43 in-line
May 13 FULC Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13 FULC Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
Muscular Dystrophy

Muscular dystrophy (MD) is a group of muscle diseases that results in increasing weakening and breakdown of skeletal muscles over time. The disorders differ in which muscles are primarily affected, the degree of weakness, how fast they worsen, and when symptoms begin. Many people will eventually become unable to walk. Some types are also associated with problems in other organs.The muscular dystrophy group contains thirty different genetic disorders that are usually classified into nine main categories or types. The most common type is Duchenne muscular dystrophy (DMD) which typically affects males beginning around the age of four. Other types include Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy. They are due to mutations in genes that are involved in making muscle proteins. This can occur due to either inheriting the defect from one's parents or the mutation occurring during early development. Disorders may be X-linked recessive, autosomal recessive, or autosomal dominant. Diagnosis often involves blood tests and genetic testing.There is no cure for muscular dystrophy. Physical therapy, braces, and corrective surgery may help with some symptoms. Assisted ventilation may be required in those with weakness of breathing muscles. Medications used include steroids to slow muscle degeneration, anticonvulsants to control seizures and some muscle activity, and immunosuppressants to delay damage to dying muscle cells. Outcomes depend on the specific type of disorder.Duchenne muscular dystrophy, which represents about half of all cases of muscular dystrophy, affects about one in 5,000 males at birth. Muscular dystrophy was first described in the 1830s by Charles Bell. The word "dystrophy" is from the Greek dys, meaning "difficult" and troph meaning "nourish". Gene therapy, as a treatment, is in the early stages of study in humans.

Browse All Tags